Intellect Neurosciences Inc. (fka ILNS)

[vegaseagle]

They do have this, and its news can be very soon.

Bapineuzumab, in Phase 3 clinical trials

Intellect Neurosciences, Inc. Encouraged by Clinical Trial Data in Relation to Its Alzheimer's Immunotherapy Patents and Technology

Bapineuzumab, in Phase 3 clinical trials, is being co-developed by Pfizer and Johnson & Johnson, and Ponezumab, in Phase 2 trials, is being developed by Pfizer. Both drug candidates are based on the use of antibodies that uniquely bind molecular signatures at the ends of beta amyloid formed when the Aß toxin is generated. This is the fundamental principle of Intellect's ANTISENILIN(R) technology, which is intended to promote the clearance of amyloid protein away from sites of damage in the brain while minimizing the potential for adverse effects that may result from less specific binding.

http://finance.yahoo.com/news/Intellect-Neurosciences-Inc-pz-4027243202.html?x=0&.v=1